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Abstract: There is an increased awareness about patients’ involvement in the clinical decision 
process where uncertainty is an unavoidable condition. The impact of psychological factors like 
risk aversion, risk aversion and time, asymmetry in risk aversion, and risk and control on shared 
decision-making is discussed. In addition to differences in risk estimates, doctors and patients 
may exhibit a difference in perception of time perspectives, and losses versus gains.
A summary of valuation factors in shared decision-making is presented: (a) the doctors tend 
to follow expected value combinations more closely, while the patient is more risk aversive; (b) 
unwillingness to take risks increases for rare outcomes; (c) there is an increased tendency to take 
risks with delayed outcomes of the decisions; (d) the doctor is generally well informed about 
risk and time aspects for different diseases, whereas this might not always be the case with the 
patient; (e) rheumatoid arthritis and diabetes mellitus are chronic diseases, and both create a 
vulnerability to a variety of complications over time; (f) rheumatoid arthritis demands different 
combinations of treatments sequentially over time, whereas diabetes mellitus is treated with 
insulin; (g) many diseases, like rheumatoid arthritis and diabetes mellitus, are not completely 
affected by control, as the disease may constantly progress.
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A 60-year-old female has had rheumatoid arthritis for 20 years, and has been treated 
with methotrexate for 5 years. Initially the effects of the treatment were positive, with 
decreased pain and disability, but now the treatment experience of the drug is not 
satisfactory. Moreover, the side effects concern the patient. Now a decision has to be 
made once again about what treatment to continue with.
A 20-year-old male in recent months has noted increased frequency of urination, 
excessive thirst, increased appetite, and weight loss. Moreover, he has noticed decreased 
energy and fatigue. He has previously been in good health. When he consulted a doctor, 
a HbA1c of 9 percentages was found, and he was diagnosed with a type 1 diabetes 
mellitus. He is now treated with insulin and has been given information about diet 
and exercise. A type 1 diabetes mellitus requires that the insulin dose always has to 
be monitored and adjusted. HbA1c is controlled, and a decision now has to be made 
about whether the insulin treatment has to be adjusted.
These are common scenarios in clinical practice. From this perspective a central 
goal is informed and shared decision-making in treatment judgments and choices. 
Actual clinical practice is not just a one-time decision for which informed consent 
is required, but a series of decisions that are part of an ongoing relationship. There 
is an increased awareness now about patients’ involvement in the clinical decision 
process, where patients and providers consider outcome probabilities and patient Therapeutics and Clinical Risk Management 2007:3(6) 1176
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preferences (Montgomery and Fahey 2001; Siminoff and 
Step 2005). Decision research, following the tradition initi-
ated by Tversky and others (Tversky and Kahneman 1986), 
has recognized expected value and probability of outcome in 
explaining judgments and decisions in various domains, and 
as being based on the products of these two parameters; the 
study of this is addressed by what is termed expected value 
of information (EVI) theory (Ades et al 2004). As Tversky 
and others have noted, actual practice in the face of uncer-
tainty is usually an iterative approach, grounded initially in a 
heuristic method of trial-and-error and evaluation (Kahneman 
and Tversky 1996).
Risk-related problems occur with treatment judgments 
and decisions, and uncertainty is an unavoidable condition 
in efforts to build a consensus about the preferred treatment 
(Edwards and Elwyn 2001a; Hall 2002). A decision will 
often have to be made about when, rather than whether, 
to undertake a risk-reducing treatment. There is evidence 
that with greater levels of informed choice, adherence to 
treatment chosen increases (O’Conner et al 1999; Arora 
et al 2005).
It is important that risk information be presented as 
something to be used as a sound basis for clinical decisions, 
for risk is not an easy concept (Iverson 2001). Information 
about both absolute and relative risk should be included, as 
they are perceived differently (Edwards and Elwyn 2001b). 
Absolute and relative risks, however, are statistical concepts, 
and further problems arise when doctors’ and patients’ 
psychological estimates of risk constitute the basis on which 
to build a consensus in order to implement a treatment 
(Loewenstein et al 2001).
The aim of the present paper is to discuss features of 
risk that are of importance for reaching consensus in shared 
decision-making applied to diabetes mellitus and rheumatoid 
arthritis. There is a current need in risk information to under-
stand the impact on shared decision-making of psychological 
factors like risk aversion, risk aversion and time, asymmetry 
in risk aversion, and risk and control.
Risk aversion
Risk aversion theory implies that one prefers the expected 
value, whereas risk seeking connotes that one prefers a 
gambling situation with an uncertain outcome of choice 
(Cher et al 1997). Individuals generally are risk aversive 
(Rosen et al 2003; Wakkar 2004). It could be speculated that 
patients are more risk aversive, as the outcomes of decisions 
have a greater impact on them. It is their body, and their life, 
that are affected by the treatment. Perhaps the doctors tend 
to follow expected value combinations more closely, while 
the patients are more risk aversive.
However, applying expected value combinations could be 
a problem for the doctor. With health outcomes, for example 
years of life gained, risk aversion is increased if beneﬁ  ts are 
nontransferable (Hoel 2003). In the judgment process the 
non-tradable risk must be accounted for in some way. One 
suggested solution (Salomon and Murray 2004) is the use of 
different measures of health that incorporate risk aversion or 
risk preference as to remaining life years or quality-adjusted 
life years.
This is information that has to be presented in a mean-
ingful way by the doctor to the patient, indeed not an easy 
task. When outcomes are calculated without taking risk into 
account, treatment choices will be overvalued. When they are 
compared with the more risky alternative, however, certain 
treatments might be undervalued (Breslow 2003). Thus, 
because some treatment programs may be undervalued due 
to a net reduction in risk, the factor of risk should be taken 
into consideration in clinical decision-making by both the 
doctor and the patient.
Bayesian studies on information processing in judgments 
have shown that unwillingness to take risks increases for rare 
outcomes (Elstein 2004). Are medical outcomes perceived as 
rare by both doctor and patient? Perhaps what is rare for the 
patient is not rare for the doctor. Risk willingness thus might 
differ between the doctor and the patient due to different 
perspectives on risk features and decision-making.
Risk aversion and time
Further complexities arise in reaching an agreement on treat-
ment, when the relationship between risk aversion and time 
aspects is considered. An increased tendency to take risks 
has been found when outcomes of the decisions are delayed 
(Watt 2000; Hojgard et al 2002). A tentative explanation is 
that a time discounting effect, lowering the estimated prob-
ability for the occurrence of distant outcomes, is operating 
here (Ortendahl and Fries 2006). So far, there has not been 
much focus upon time aspects in shared decision-making. 
Perhaps the time perspective of the doctor is different from 
the time perspective of the patient, both objectively and 
subjectively. The doctor is generally well informed about 
risk and time aspects for different diseases, and this is not 
always the case with the patient.
Decision-making is often driven by the overwhelming 
impact of the acute medical problem on all aspects of the 
individual’s life. With chronic conditions, patients must 
make multiple and repetitive decisions, with variable Therapeutics and Clinical Risk Management 2007:3(6) 1177
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outcomes, about how they will live with their chronic 
condition. Both rheumatoid arthritis and diabetes mellitus 
are chronic diseases. Symptoms of rheumatoid arthritis are 
persistent joint pain which is aggravated by movement or 
activity such as walking, getting up from a chair, holding 
an object. There is an inﬂ  ammation, indicated by joint 
swelling, stiffness, redness, and warmth, which destroys 
cartilage, bone, and ligaments, leading to possible deformity 
and disability.
Diabetes mellitus is a group of metabolic disorders with 
one common manifestation: hyperglycemia. Symptoms of 
type 1 diabetes are increased thirst, increased urination, 
weight loss in spite of increased appetite, fatigue, nausea, 
and vomiting. Diabetes creates a vulnerability to a variety of 
complications over time. Control of blood sugar is the best 
way to minimize the risk of complications, but the risk of 
complications increases with the length of time the patient 
has had the disease. Diabetes complications affect the eyes, 
kidneys, nerves, and large and small blood vessels.
These complications could occur at different points of 
time. Moreover, changes could occur in judgments over 
time for both the doctor and the patient. Risk aversion can 
decrease or increase over time as the patient gains more 
experience with a chronic illness. The patient has to live 
with the risk that the disease might progress, and that the 
effectiveness of the treatment decreases over time. For a 
patient with type 1 diabetes the risk and uncertainty could 
vary in the course of the same day, as the blood glucose 
level varies with the amount of exercise and the food intake. 
For type 1 diabetes the treatment is to take insulin, but the 
dosage may vary.
Rheumatoid arthritis might demand different combina-
tions of treatments sequentially over time. Depending on 
symptoms, treatment chosen could be conservative, involving 
aspirin or one of the NSAIDs. In a more aggressive treat-
ment methotrexate could be added to the regimen. Other 
treatment options are steroids and Plaquenil (Tsakonas et al 
2000). There are numerous other treatments which are used 
in conjunction with one another, or alone, that manage the 
disease for patients with mild or moderate disease (Doan 
and Massarotti 2005). Beyond that, a newer class of drugs 
known as TNF blockers could be prescribed (Coenen et al 
2007). Exercise programs, physical therapy and surgery 
are complementary treatments. For rheumatoid arthritis the 
expected value of a speciﬁ  ed treatment could be estimated 
for different periods, with the traditional decision-making 
paradigm repeated for different periods (Ortendahl et al 
2000). The optimizing of sequences of medical treatments 
is another issue related to risk and time that needs further 
attention.
With regard to issues of risk and time in relation to 
health behavior, a study of smokers who had failed in their 
attempt to quit smoking found that their level of perceived 
risk declined over time (Gibbons et al 1991). While the situ-
ation of patients with a disease differs from that of people 
confronting preventive procedures, it could be contended 
that the study’s ﬁ  nding has an application in the domain of 
treatment. That is, in order to maintain motivation and com-
pliance with the chosen treatment of a disease, information 
on medical decision-making should be framed to counteract 
the tendency for risk perception to decline.
Asymmetry in risk aversion
The salience of both negative and positive consequences has 
been found to diminish with distance to the goal, though in fact 
the saliency decreases faster for negative outcomes (Berndsen 
and van der Plight 2001). Moreover, an earlier study found an 
asymmetry in risk aversion (Kahneman and Tversky 1979), 
with a preference for certain over uncertain gains, whereas 
for losses uncertainty was preferred to certainty.
When applied to health behavior and shared decision-
making, such an asymmetry may have importance, since 
the immediate action could give a loss with a high degree of 
certainty (Gyrd-Hansen et al 2003). For the individual patient 
the gain obtained in the future by treatment is uncertain, 
despite its being predictable for the patient population as a 
whole. Further problems, discussed previously (Ortendahl 
and Fries 2002), then arise related to gains and losses in 
treatment, as doctors and patients may perceive losses and 
gains in different ways, something that makes it more difﬁ  cult 
to reach a high level of consensus.
Both rheumatoid arthritis and diabetes mellitus are chronic 
diseases demanding life-long treatments. Both carry a high 
risk of constant deterioration in health in several respects. The 
patient with type 1 diabetes has to maintain normal glucose 
levels and the patient with rheumatoid arthritis has to endure 
different medical regimens. Despite this strict treatment, 
the result might be only to lessen the slope of decrement, 
with a negative end result for the disease process itself. 
Deterioration from the disease is a loss; recovering from or 
avoiding the progression of the disease is a gain.
The treatment is necessary for medical reasons, and that 
necessity is the motivating factor for continuing treatment 
despite its adverse effects. Efﬁ  cacy can then be regarded as 
a gain, and toxicity as a loss when treating a disease. Perhaps 
side effects like nausea or headache, for example, have a Therapeutics and Clinical Risk Management 2007:3(6) 1178
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larger impact on judgments and treatments chosen by the 
patient compared to the doctor.
Risk and control
Many diseases are not completely affected by control, 
as the disease may constantly progress. One example is 
cancer, which treatment might control only to some extent 
(Myers 2005). The patient can control a disease like type 
1 diabetes to a larger extent by taking insulin, exercising 
and eating the right food. Rheumatoid arthritis is another 
disease that to some extent might be controlled through 
treatment with certain drugs in spite of its progress. Con-
trol over the progress of the disease is difﬁ  cult to achieve, 
but the patient and the doctor might gain some degree of 
control over it by following certain treatments (Ortendahl 
et al 2000).
In the same study on rheumatoid arthritis a low reten-
tion rate in taking methotrexate was related to a high initial 
level of pain. One explanation for this result was that when a 
patient is in a poor state of health, every potential treatment 
might be tried with little patience. High level of pain is prob-
ably associated with high disease activity and severe disease. 
It is possible then that methotrexate is insufﬁ  cient to manage 
the disease, and therefore more advanced, and perhaps even 
experimental or novel treatments need to be considered. The 
patience at issue might be both the doctor’s and the patient’s. 
The patient’s because he or she does not like being unable 
to drink alcohol and feeling nauseated from the medication. 
Or the physician’s, if there is an interest in pursuing a more 
aggressive therapy to get a faster result and reduce the risk 
of permanent joint deformity.
On the other hand, it might be easier to experience 
improvement with new drugs when patients are starting 
from a poor state of health, motivating them to continue the 
therapy, and yet this was not the case. The result could also 
be explained by a discrepancy between doctors’ prescriptions 
and the pain assessed by the patient, as the doctor might have 
based the treatment on other variables.
Thus, the study indicates the importance of communi-
cation and shared decision-making to increase compliance 
with the treatment chosen. The control perceived by the 
patient might increase when the patient is given informa-
tion about the progress of the disease, the loss of health if 
the disease went untreated, and the gain if the treatment is 
complied with. Recent research on framing health informa-
tion has indicated that compliance is affected by whether 
the information is framed as a gain or a loss (Ortendahl 
and Fries 2005). Having a disease is a situation in which 
the patient is already in a loss situation; this makes the 
framing of messages more complex. A study by Armstrong 
et al (2002) found that stating chance of death over time 
resulted in lower levels of understanding and less interest 
in preventive surgery than framing statements as chance of 
survival over time.
Control might be achieved to a larger extent in preventive 
procedures. Through life-style choices, the patient can 
increase the probability of preserving health. If no disease 
develops where progress is beyond the control of the doctor 
and the patient, no treatment judgments and choices have 
to be made.
Implications for clinical work
Informed and shared decision-making is complex, and many 
issues have been raised in the present article (see Table 1).
How are sound treatment decisions determined? Are 
they based on value of the outcome, the probability of the 
outcome? Are judgments and decisions based on both vari-
ables or are simplifying strategies used based on only one 
of the variables?
The application of evidence-based medicine requires 
the combination of scientiﬁ  c facts with value judgments, 
and the cost of different treatments (Jenicek and Stachenko 
2003; Saarni and Gylling 2004). This procedure could be 
approached from the perspective of doctors or of individual 
patients. Studies of medical decision-making usually provide 
information about the outcomes of clinical decisions but 
little information about the process of the decision (Teutsch 
2003). Doctors may not value different aspects of health in 
the same way as patients, and studies on patient control have 
Table 1 Valuation factors in shared decision-making
•  The doctor tends to follow expected value combinations more
  closely, while the patient frequently is more risk aversive
•  Unwillingness to take risks increases for rare outcomes
•  There is an increased tendency to take risks when decisions have 
 delayed  outcomes
•  The doctor is generally well informed about risk and time aspects
  for different diseases, whereas this might not always be the case
  with the patient
•  Rheumatoid arthritis and diabetes mellitus are chronic diseases,
  and both create a vulnerability to a variety of complications
 over  time
•  Rheumatoid arthritis demands different combinations of
  treatments sequentially over time, whereas diabetes mellitus is
  treated with insulin
•  Many diseases, like rheumatoid arthritis and diabetes mellitus,
  are not completely affected by control, as the disease may
 constantly  progressTherapeutics and Clinical Risk Management 2007:3(6) 1179
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found that patients generally respond positively to increased 
information (Auerbach 2000).
However, research in cognitive psychology has shown 
that people are quickly overwhelmed by having to consider 
more than a few options in making choices (Ubel and 
Loewenstein 1997). Therefore, decision analysis, based 
on the concepts of value and risk, provides a quantiﬁ  able 
way to choose between options and might be expected to 
facilitate clinical judgments and shared decision-making. 
Overall, likelihood of a speciﬁ  c adverse outcome should 
be a parameter affecting the estimate of future risk and its 
consequences. Risk estimates of future outcomes could be 
based on an outcome in the future having less importance 
than one in the present, and where the adverse outcome may 
have different values to the doctor and the patient.
Another parameter is temporal distribution of risk not 
being homogenous throughout the life-span of the individual. 
Speciﬁ  c individual factors modify the risk for a speciﬁ  c 
person, and person-speciﬁ  c modiﬁ  ers are likely distributed 
differently in time. Severity of a disease may not be the same 
for everyone who experiences the disease. One example is 
occupational back pain being relatively mild in some persons 
but disabling in others (Staiger et al 2005).
Further complexities arise with decision analytic models 
applied to different diseases, like rheumatoid arthritis and dia-
betes mellitus. Rheumatoid arthritis gives different symptoms 
like pain and disability. Should pain or disability or both con-
stitute the basis for the process of the decision, and the assess-
ment of outcomes? What is the estimate of probability that 
one or both of the symptoms will decrease with the treatment 
chosen? How are pain and disability experienced subjectively 
by the patient? For the doctor disability is more apparent and 
objective, whereas the pain, which is subjectively experienced 
by the patient, might be more difﬁ  cult to endure.
There is an ongoing discussion about complications or 
longer term consequences of the disease or of poorly man-
aged disease. With rheumatoid arthritis, there is an additional 
level of complexity involving complications and risks asso-
ciated with treatment, including methotrexate, steroids, and 
even anti-TNFs. This may be an additional wrinkle in the 
decision-making process, implying that treatment itself is 
not a cure-all, or close to it, with inherent risks.
Moreover, in rheumatoid arthritis the effectiveness of a 
drug may decrease after a period of time. In a study on the 
methotrexate therapeutic response (Ortendahl et al 2002) 
it was found that disability began to re-progress after 42 
months, with a re-progression to baseline after 8 or more 
years. The treatment of rheumatoid arthritis implies a succes-
sion of single or multiple drugs with decision points where 
the next drug is chosen. Therefore, risks must be considered 
repeatedly in sequences.
For patients with type 1 diabetes the level of blood glu-
cose measured by HbA1c is the basis for a decision to start a 
treatment with insulin. Other treatments like exercise and diet 
usually are not sufﬁ  cient to regulate the blood glucose level. 
The treatment with insulin, which is life-long, decreases the 
risk of late complications, and HbA1c is regularly measured 
to assess the effectiveness of the treatment.
Final comments
From the discussion above, it is evident that there could be 
a discrepancy in risk estimates between the doctor and the 
patient, both objectively and subjectively, with an impact on 
the patient’s compliance level to prescriptions and treatments. 
Therefore, features of risk should increasingly be stressed 
in clinical decisions based on mutual agreement (Feldman 
et al 2002; Fierz 2004).
The present article has initiated a discussion of what 
doctors and patients could do about risk-related aspects in 
health, and how risk dimensions of health should be taken 
into account in clinical decision-making. It is evident that 
introducing features of risk, like risk aversion, risk aversion 
and time, asymmetry in risk aversion, and risk and control, 
provides a more complete, if more complex, picture of clini-
cal judgment analysis as a foundation for the doctor and the 
patient. It could be concluded that the process of attaining 
shared goals should be based on risk aspects and a realistic 
decision analysis. However, further research is required 
to understand the variations in doctors’ and patients’ risk 
preferences in shared decision-making.
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